 |
Strategic planning & monitoring =>> Monitoring progress =>>
Process to monitor progress of GAVI and respond to emerging needs established and ongoing.
| Status |
Achievement of overall target |
| Mostly on track
|
• Estimations of 2003 progress done, agreed process with partners for continuous annual monitoring.
• ISS study part A carried out, disease impact studies prepared, immunization safety assessments partly completed, waste management assessment delayed.
• The Hib surveillance network was initially delayed but is now catching up. GAVI funds did not arrive until the second quarter of 2004.
|
Responsible entity: Secretariat
Completed by: December 2005
Total budget: $3,266,000
Target description and how it will help reach GAVI milestones
Monitoring GAVI progress is done through monitoring achievement towards objectives and milestones and conducting relevant studies. This includes disease surveillance related to hepB, YF, and Hib.
HIB AND HEPB MILESTONES: Studies will allow a better estimation of the impact of GAVI support and provide a guide for a more suitable ways to provide support.
The Hib surveillance network will continuously monitor the impact of Hib introduction in Africa.
Justification for selection of activities
The Board has already agreed to conduct a study to assess GAVI performance system. There is a clear need to undertake studies to assess the impact of GAVI on disease burden (Hepatitis B, Hib, yellow fever), safety of injection and wastage rates.
ACTION PLAN | Activities | Budget | Coordinating partner/ support partners | Expected outcomes | | Monitoring countries and GAVI global progress | $296,000 | Secretariat WHO | • Annual report produced | | Special studies to measure the impact of GAVI support | $1,760,000 | Secretariat WHO CDC | • Evaluation of the performance based grants system,
• Vaccine wastage rate assessment,
• hepB impact assessment,
• Yellow Fever impact assessment,
• Injection safety impact assessment,
• Hib impact assessment | | Coordinate Hib surveillance network | $1,210,000 | WHO | • 26 AFRO country sites monitoring bacterial meningitis incidence |
Detailed information on activities
Activity 1:
Analysis of country and global progress towards milestones including cost effectiveness analyses and assessments of deaths averted at country level and monitoring of supply and disbursement.
Activity 2: - Hib impact assessment in countries receiving Hib vaccines and review of AFRO situation (to be conducted during 2004 and 2005, estimated annual cost: $150,000) resulting in $300,000
- Wastage assessment in countries using combination vaccines, to be conducted during 2004 and 2005, estimated annual cost : $130,000) resulting in $260,000
- Joint GAVI/GF assessment of performance based systems : $400,000 in 2004
- HepB assessment study to be conducted during 2003-2004 : $250,000
- Yellow Fever vaccine impact assessment to be conducted during 2003 and 2004 : $300,000
- Injection safety support assessment, to be conducted during 2003 and 2004: $250,000
Activity 3:
The AFRO Pediatric Bacterial Meningitis surveillance network, managed by WHO: the money will be used to maintain 28 existing sites, bacteriological reference laboratories and expanding network to additional priority countries.
|
|
|
|
Targets by priority area
Strategic planning & monitoring
==>> Setting priorities
==>> Monitoring progress
• Process to monitor progress of GAVI and respond to emerging needs established and ongoing.
Other
==>> Alliance coordination
Strengthening service delivery
==>> Health information and monitoring systems
==>> Contributing to alleviation of system-wide barriers
==>> Enhanced efforts in large population countries
Ensuring access to vaccines and related products
==>> Procurement/Supply of existing products
==>> Development and introduction of new, near-term products
==>> Managing process for country support from Vaccine Fund
Securing long-term financing
==>> Financial sustainability
==>> Recapitalization of The Vaccine Fund
|
|